Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Peripheral Stent Implants Market size was over USD 4.6 billion in 2024 and is projected to reach USD 9.7 billion by the end of 2037, increasing at a CAGR of 6.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of peripheral stent implants is evaluated at USD 4.9 billion.
Peripheral stent implants are extremely crucial for aiding peripheral artery disease (PAD) by reestablishing blood flow to tapered or congested arteries in the legs and other areas. These implants operate by upholding artery patency, releasing PAD symptoms, including pain and improved flexibility, and avoiding further difficulties. According to a clinical study published by Diagnostic and International Radiology in January 2025, 40 patients were treated with iCover balloon-expandable covered stents with a technical success rate of 100%. Additionally, the target lesion revascularization rate was 95.8%, the initial patency rate was 91.7%, and the secondary patency rate was 95.8% within six months, thus driving the market.
Furthermore, the development of the market is possible with the pricing strategy that highly depends upon policies imposed by regulatory organizations including the National Pharmaceutical Pricing Authority (NPPA). This particular organization possesses the responsibility of setting the ceiling price of different types of stents across nations. According to the 2022 Fortis Healthcare report, the cost of a stent depends on the brand and the manufacturer, such as the manufacturer of XIENCE XPEDITION 48 is Abbott Vascular, which commercializes stents at USD 38,265.07. Besides, healthcare facilities bill patients for implantation procedures with medication charges, leading to a final price, thereby amplifying the market globally.
Other Stents Based on Brand and Manufacturer
|
Brand Name |
Manufacturer |
Price |
|
Biomatrix Alpha |
Biosensor |
USD 38,265.07 |
|
Mitigator |
Envision Scientific |
USD 22,500.0 |
|
Release-R |
Relisys |
USD 7,950.0 |
|
Sirolimus |
S3V Vascular Technologies |
USD 30,811.0 |
|
Evermax |
Nano Therapeutics |
USD 8,100.0 |
Source: Fortis Healthcare 2022
Peripheral Stent Implants Sector: Growth Drivers and Challenges
Growth Drivers
- Rising occurrence of peripheral vascular diseases: This condition has gained increased and widespread popularity, which is the ultimate growth factor for the peripheral stent implants market. According to an article published by the Journal of Vascular Surgery in April 2023, there has been an increase in the global incidence of peripheral artery disease by 72% from 65,764,499 to 113,443,016 persons. In addition, the incidence further increased to 13% per 100,000 persons, and it decreased to 22% per 100,000 age-standardized. Therefore, this denotes a huge demand for peripheral stent implantation as a suitable treatment procedure.
- Application of regenerative medication: This is another factor that effectively drives the expansion of the market. As stated in the 2025 WHO report, 17.9 million people faced death due to cardiovascular disorders, with coronary artery disease being the common type affecting almost 18.2 million adults, especially in the U.S. Hence, the implementation of regenerative stent technology such as cell-capture coatings, cell-adhesive peptides, stents with cell secretomes, and bioresorable materials are useful to catering to these health conditions, thus enhancing the market demand internationally.
Challenges
- Expensive production costs: The aspect of innovation and technological advancement in designing and using materials has resulted in the huge cost of stent implants, which causes a hindrance in the growth of the peripheral stent implants market across nations. This has eventually resulted in the skyrocketing of the overall production costs, especially for drug-eluting stents. This particular stent type is usually high on the price strategy in comparison to other types, thus deliberately creating a barrier for the market upliftment worldwide.
- Poor access to health insurance: The negative impact of the market is also due to the presence of poorly administered health insurance. This is increasingly common among developing nations, wherein there is poor accessibility and the population readily suffers from a huge health and disease burden. It is only in nations with a developed economy that the availability of standard health policies and insurance is readily available. Therefore, it is the responsibility of the administrative personnel to ensure suitable insurance facility.
Peripheral Stent Implants Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 4.6 billion |
|
Forecast Year Market Size (2037) |
USD 9.7 billion |
|
Regional Scope |
|
Peripheral Stent Implants Segmentation
Product (Bare Metal Stents (BMS), Covered Stents, Drug-Eluting Stents (DES))
Based on the product, the bare metal stents (BMS) segment is expected to hold the largest share of 80.5% in the peripheral stent implants market by the end of 2037. This growth is attributed to the robustness and structural integrity of these stents. As per the September 2024 China Chemical Letters article, the BMS comprises a high restenosis rate, ranging between 20% to 30% post the surgical procedure. Hence, this particular stent product plays a pivotal role in ensuring standard treatment to aid peripheral artery conditions by sustaining vessel patency while guaranteeing optimum blood flow, thus suitable for the segment’s development.
Artery Type (Iliac Stents, Femoral-popliteal Stents, Renal and Related Stents, Carotid Stents)
Based on the artery type, the iliac stents segment is projected to garner a share of 52.2% in the peripheral stent implants market by the forecast period. This particular artery-based stent is designed to cater to iliac arteries, which source blood to the pelvis and legs, accounting for their durable market position. As per a clinical study published by NLM in March 2024, 133 patients were evaluated, out of which 65.4% underwent stenting and the remaining 34.6% received balloon angioplasty. The instant technical success rate was 97.7%, while the medical success rate was 62.4%, thereby driving the segment’s upliftment globally.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Artery Type |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPeripheral Stent Implants Industry - Regional Synopsis
North America Market Analysis
North America’s peripheral stent implants market is anticipated to garner the highest share of 47.2% by the end of the forecast timeline. This growth is attributed to the rising incidence of the condition in the region, which is caused due to the surge in smoking rates, along with inactive lifestyles in combination with subpar diet choices. All these factors eventually lead to cardiovascular and cerebral disorders, diabetes, and further affect the aging population, thereby enhancing the market demand in the region.
The market in the U.S. is gaining more exposure owing to the presence and responsibilities undertaken by regulatory bodies. For instance, in March 2023, the U.S. FDA approved the commercialization of Onyx Frontier Zotarolimus-Eluting Coronary Stent System and Resolute Onyx Zotarolimus-Eluting Coronary Stent System. Both these devices comprise a metal stent made out of cobalt alloy, suitable to treat a conical blood vessel (coronary artery) caused by coronary artery disease. The stent is covered with the drug zotarolimus and a polymer varnish to deliver the drug at a measured rate.
The growth of the peripheral stent implants market in Canada highly depends on funding strategies initiated by the government. For instance, as stated in the August 2021 Ontario Canada report, the regional government made an investment of USD 5.2 million to effectively support the planning and design of a cardiovascular surgery program that will ensure rapid heart care for people in Ontario. Furthermore, the government has provided a fund of USD 700,000 for establishing a catherization laboratory and providing implantable cardioverter-defibrillator, thus driving market upliftment.
APAC Market Statistics
The Asia Pacific peripheral stent implants market is projected to be the fastest-growing region during the forecast timeline. This growth is fueled by the rise in the geriatric population and the adoption of sedentary and unhealthy lifestyles, thus driving the increase in the demand for suitable treatment options in the region. In addition, the availability of government and administrative strategies that include favorable reimbursement policies, disease prevention programs, and public awareness campaigns are also responsible for the amplification of the market in the region.
The market in India is significantly growing since international organizations are initiating effective contributions. For instance, in May 2024, Abbott declared the inauguration of XIENCE Sierra Everolimus Eluting Coronary Stent System in the country. It is one of the state-of-the-art generation stents in the XIENCE family, currently accessible to people suffering from blocked coronary arteries. Besides, this stent system provides incomparable safety to the most multifaceted cases for interventional cardiologists, thus an optimistic outlook for the market to expand in the country.
The peripheral stent implants market in China is experiencing advancements by including the evolution of long-lasting as well as biodegradable stents and technology such as the presence of transradial access (TRA) in peripheral interventions. According to a study published by NLM in September 2022, 178 patients suffering from symptomatic peripheral artery disease were evaluated at nine health institutions in the country. The implementation of the Zilver PTX drug-eluting stent as a treatment solution constituted a success rate of 81.9% for the primary year. Additionally, the event-free survival rate was 94.9%, and the target lesion revascularization, thus boosting the market in the country.
Companies Dominating the Peripheral Stent Implants Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biotronik
- Cardinal Health
- Cook Medical
- iVascuar SLU
- Medtronic
- MicroPort NeuroTech
- Boston Scientific Corporation
- Royal Philips
- Imperative Care
Key organizations in the market are familiarizing progressive products at reasonable prices to upsurge their market share and applying tactical initiatives, such as procurements, mergers and acquisitions, and collaborations to capitalize their market dominance. For instance, in June 2024, Boston Scientific Corporation stated its agreement to acquire Silk Road Medical, Inc. at a purchase price of USD 27.50 per share, which reflects an enterprise value of an estimated USD 1.16 billion. The purpose of this was to demonstrate Boston’s continuous assurance to deliver evocative revolution for physicians who care for patients with peripheral vascular disease, thus suitable for the market upliftment.
Here's the list of some key players:
In the News
- In June 2024, Royal Philips notified the initial implant of the Duo Venous Stent System, which is an implantable medical device specified to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency, following premarket approval from the U.S. FDA.
- In December 2023, Imperative Care publicized the commencement of a first-in-human clinical study for its innovative stent system designed to require only a single antiplatelet therapy for patients enduring stent-assisted treatment of wide-neck intracranial aneurysms.
Author Credits: Radhika Pawar
- Report ID: 7591
- Published Date: May 07, 2025
- Report Format: PDF, PPT
